NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells

作者：Zhou, Ya; Zhu, Yuanyuan; Fan, Xiaoyan; Zhang, Chundong; Wang, Yitao; Zhang, Lian; Zhang, Huan; Wen, Tao; Zhang, Kaina; Huo, Xiao; Jiang, Xue; Bu, Youquan; Zhang, Ying^*

来源：Oncotarget, 2017, 8(20): 33110-33121.

DOI：10.18632/oncotarget.16145

• ovarian cancer
• NID1
• EMT
• metastasis
• chemoresistance

Nidogen-1 (NID1) has been identified as a novel candidate diagnostic biomarker of ovarian cancer in our previous study. Nevertheless, the role of NID1 in the pathogenesis of ovarian cancer is unclear. In the present study, we demonstrated that NID1 was a mesenchymal associated gene and its high expression was significantly correlated with shorter overall survival of ovarian cancer patients. The ectopic expression of NID1 in OVCAR-3 cells revealed a epithelial-mesenchymal transition (EMT) phenotype accompanied by enhancement of motility, invasiveness and cisplatin resistance, whereas the knockdown of NID1 was sufficient to convert HEY cells into epithelial phenotype with decreased capability of motility, invasiveness and cisplatin resistance. Mechanistic studies disclosed that NID1 activated ERK/MAPK signaling pathway to promote EMT. Collectively, our findings have uncovered the molecular mechanisms of NID1 in promoting ovarian cancer metastasis and chemoresistance, and provide a rationale for the therapeutic potential of NID1 suppression in ovarian cancer.

• 出版日期2017-5-16
• 单位重庆医科大学